Reversion From Chronic to Episodic Migraine and Effects on Patient-reported Outcomes Following Treatment With Erenumab: Post-hoc Analysis of the Randomised, 12-week, Double-blind DRAGON Study

被引：0
|
作者：
Wang, Shuu-Jiun [1 ]
Kim, Byung-Kun [2 ]
Wang, Hebo [3 ]
Zhou, Jiying [4 ]
Wan, Qi [5 ]
Yu, Tingmin [6 ]
Lian, Yajun [7 ]
Arkuszewski, Michal [8 ]
Ecochard, Laurent [8 ]
Wen, Shihua [9 ]
Yin, Fangfang [10 ]
Li, Zheng [10 ]
Su, Wendy [9 ]
Yu, Shengyuan [11 ]
机构：
[1] Taipei Vet Gen Hosp, Neurol Inst, Taipei, Taiwan
[2] Eulji Univ, Nowon Eulji Med Ctr, Sch Med, Seoul, South Korea
[3] Hebei Gen Hosp, Shijiazhuang, Peoples R China
[4] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[5] Jiangsu Prov Hosp, Nanjing, Peoples R China
[6] Second Hosp Jilin Univ, Changchun, Peoples R China
[7] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[8] Novartis Pharma AG, Basel, Switzerland
[9] Novartis Pharmaceutical Corp, E Hanover, NJ USA
[10] China Novartis Inst Biomed Res Co Ltd, Shanghai, Peoples R China
[11] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
来源：
CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS22-EP-
引用
收藏
页码：29 / 31
页数：3
相关论文
共 50 条
  • [21] Post-hoc Outcomes from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache
    Kudrow, D.
    Oakes, T. M.
    Bardos, J.
    Andrews, J.
    Rettiganti, M.
    Zhou, C.
    Riesenberg, R.
    Wenzel, R.
    Kuruppu, D.
    Martinez, J.
    HEADACHE, 2019, 59 : 193 - 193
  • [22] History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release
    Pae, Chi-Un
    Masand, Prakash S.
    Marks, David M.
    Krulewicz, Stan
    Han, Changsu
    Peindl, Kathleen
    Mannelli, Paolo
    Patkar, Ashwin A.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2009, 10 (04): : 435 - 441
  • [23] Longitudinal patient-reported outcomes (PRO) in subjects with refractory pain associated to Trigeminal Neuralgia:: A post-hoc analysis of a 12-week prospective study in primary care setting (PCS) under routine medical practice
    Saldana, M. M.
    Perez, C.
    Navarro, A.
    Martinez, S.
    Rejas, J.
    VALUE IN HEALTH, 2007, 10 (06) : A392 - A392
  • [24] Patient-Reported Outcomes in Chronic Migraine Patients with Prior Prophylactic Treatment Failure Receiving Placebo or Erenumab: Subgroup Analysis of a Pivotal Randomized Study
    Lanteri-Minet, M.
    Buse, D. C.
    Starling, A. J.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, S.
    Desai, P.
    Cheng, S.
    Klatt, J.
    Mikol, D.
    HEADACHE, 2018, 58 : 170 - 171
  • [25] Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
    Kaname Ueda
    Wenyu Ye
    Louise Lombard
    Atsushi Kuga
    Yongin Kim
    Sarah Cotton
    James Jackson
    Tamas Treuer
    The Journal of Headache and Pain, 2019, 20
  • [26] Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
    Ueda, Kaname
    Ye, Wenyu
    Lombard, Louise
    Kuga, Atsushi
    Kim, Yongin
    Cotton, Sarah
    Jackson, James
    Treuer, Tamas
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1):
  • [27] Treatment Effects of Celecoxib Oral Solution in Migraine With Aura and Without Aura: Post-Hoc Analysis of Results From Two Randomized, Double-Blind Placebo-Controlled Trials
    Tepper, Stewart
    Serrano, Daniel
    Ko, Mancia
    Kunkel, Todd
    Lipton, Richard
    NEUROLOGY, 2023, 100 (17)
  • [28] Treatment effects of celecoxib oral solution in migraine with aura and without aura: Post-hoc analysis of results from two randomized, double-blind placebo-controlled trials
    Tepper, S. J.
    Serrano, D.
    Iaconangelo, C.
    Lipton, R. B.
    HEADACHE, 2022, 62 : 168 - 169
  • [29] A post-hoc subgroup analysis in participants with migraine with aura from the TEAM (a phase 3 randomized, double-blind, sham- controlled Trial of e-TNS for the Acute treatment of Migraine) study
    Kuruvilla, D.
    Panza, G.
    Johnson, M.
    HEADACHE, 2023, 63 : 115 - 116
  • [30] Efficacy of erenumab (AMG 334) in chronic migraine patients with prior prophylactic treatment failure: Subgroup analysis of the phase 2, randomised, double-blind, placebo-controlled study
    Ashina, Messoud
    Tepper, Stewart J.
    Brandes, Jan Lewis
    Reuter, Uwe
    Boudreau, Guy P.
    Dolezil, David
    Cheng, Sunfa
    Leonardi, Dean
    Lenz, Robert A.
    Klatt, Jan
    Mikol, Daniel D.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
12345